Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 679

The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Open access
Yuan, Min, Huang, Li-Li, Chen, Jian-Hua, Wu, Jie, Xu, Qing·2019·Signal Transduction and Targeted Therapy

Abstract

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient’s tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-019-0099-9

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 159 references

Cited by

See all 679

Metadata

Authors
Yuan, M., Huang, L.-L., Chen, J.-H., Wu, J., & Xu, Q.
Venue
Signal Transduction and Targeted Therapy
Published
2019-12-17
Volume
4
Issue
1
Pages
61-61
ISSN
2059-3635 (ISSN-L)
OpenAlex
W2994642443
Cited by
679
References
159
FWCI
58.81
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. https://app.cochat.ai/papers/10.1038/s41392-019-0099-9
The paper
Yuan, M., Huang, L.-L., Chen, J.-H., Wu, J., & Xu, Q. (2019). The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-019-0099-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.